FLT3 and acute myeloid leukemia: After stratification, the results were incorporated into clinical trials, including all-trans retinoic acid (ATRA) plus arsenic trioxide for acute promyelocytic leukemia (APL0406, [13]), and FLT3-ITD-positive AML treated with midostaurin plus chemotherapy and allogeneic transplantation (AMLSG16-10, [14]), among several others.